Updated on 20 February 2014
Another trend that we are seeing is that many biopharma companies have established tighter internal procedures for assessing their vendors, including suppliers of services. The overall supply chain has come under intensive scrutiny by regulatory agencies, partly due to the increase use of outsourcing services and also partly due to new and more restrictive Good Distribution Practices (GDP) guidelines.
As a result of enhanced quality standards and a stronger focus on regulatory compliance, FedEx Express is experiencing a drastic increase in the number of inquiries about quality safeguards related to general quality matters with FedEx shipping practices and procedures, especially in Western Europe and North America.
FedEx offers many different types of services to support the healthcare companies' efforts to track performance and ensure a more efficient and effective supply chain. For example, through use of the FedEx innovations like the SenseAware platform, temperature measurements can be monitored in near-real time and analyzed afterwards. In the event any transportation-related problems arise, shippers can request Corrective and Preventive Actions (CAPA) or file a Supplier Corrective Action Request (SCAR) form or even decide to disqualify a vendor temporarily. Investigations are carried out internally by the vendor to determine root causes and find robust solutions.
Indeed, while multi-sensor devices such as the FedEx SenseAware platform are already available for use on all transport modes in over a dozen international locations, by 2033, the use of sensors will be ubiquitous.
We envision that the biopharma supply chain of the future will be underpinned by both visibility and flexibility. It will radiate visibility with tiny embedded sensors, enabling an unparalleled degree of real-time tracking and tracing.